Coronavirus (COVID-19) Update
STUART, FL. March 26, 2020 -
To Our Valued Linical Clients and Partners,
Together, we are facing a truly unprecedented situation. The global coronavirus pandemic is requiring us all to be vigilant and do our part in reducing risks and ensuring the health and safety of our employees, families, communities, and the patients we serve. This is our highest priority. With the ongoing spread of COVID-19 and the incredible speed at which things are changing around us, Linical is closely monitoring the situation while taking proactive precautions to ensure the safety of our employees as well as the continuity of our business operations and services.
Regarding our business operations, the entire Linical team is and will continue to be fully operational. We have implemented our Business Continuity Plan to ensure normal operations, including further enabling our remote working environment. As always, we are committed to providing exceptional communication and stability in our clinical programs, even in times of uncertainty. Our commitment will not waver throughout this situation as it improves and ultimately returns to normal.
Like many companies, and in the interest of our employees’ safety, we have significantly restricted travel worldwide. All of our employees around the world have been strongly encouraged to work from home. With our highly-distributed workforce and many of our employees typically working remotely, this shift has been relatively smooth and we will continue to deliver the highest levels of quality, availability, and continuity.
Thank you for your continued partnership and we wish you health and safety during this difficult time.
Vita M. Lanoce
Chief Executive Officer
Linical Accelovance Group
Interested in bringing a COVID-19 treatment to market? As a leading infectious disease CRO, Linical has deep clinical experience in vaccine drug development programs. Linical has been at the forefront of vaccine and infectious disease research for more than a decade, including the Ebola outbreak in 2014-2016. Today we are committed to helping companies bring coronavirus treatments to market, rapidly and cost-effectively. Learn more about our infectious disease experience.